See more : Sampo Oyj (SAXPY) Income Statement Analysis – Financial Results
Complete financial analysis of Kinnate Biopharma Inc. (KNTE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Kinnate Biopharma Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Fosun International Limited (0656.HK) Income Statement Analysis – Financial Results
- Pop Culture Group Co., Ltd (CPOP) Income Statement Analysis – Financial Results
- Predilife S.A. (ALPRE.PA) Income Statement Analysis – Financial Results
- Sandfire Resources America Inc. (SRAFF) Income Statement Analysis – Financial Results
- DCM Financial Services Limited (DCMFINSERV.NS) Income Statement Analysis – Financial Results
Kinnate Biopharma Inc. (KNTE)
About Kinnate Biopharma Inc.
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 799.00K | 604.00K | 123.00K | 83.00K | 0.00 | 0.00 |
| Gross Profit | -799.00K | -604.00K | -123.00K | -83.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 90.77M | 88.15M | 67.17M | 29.24M | 8.96M | 5.68M |
| General & Administrative | 0.00 | 30.37M | 22.95M | 6.76M | 3.06M | 1.96M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.44M | 30.37M | 22.95M | 6.76M | 3.06M | 1.96M |
| Other Expenses | 0.00 | 2.25M | 348.00K | -5.00K | 0.00 | 0.00 |
| Operating Expenses | 118.21M | 118.52M | 90.11M | 36.00M | 12.01M | 7.63M |
| Cost & Expenses | 119.01M | 118.52M | 90.11M | 36.00M | 12.01M | 7.63M |
| Interest Income | 8.53M | 0.00 | 348.00K | 245.00K | 43.00K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 799.00K | 604.00K | 123.00K | 83.00K | 171.86K | 161.14K |
| EBITDA | -118.21M | -117.92M | -89.99M | -35.92M | -12.01M | -7.63M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -119.01M | -118.52M | -90.11M | -36.00M | -12.01M | -7.63M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 6.36M | 2.25M | 348.00K | 240.00K | 43.00K | 0.00 |
| Income Before Tax | -112.65M | -116.27M | -89.76M | -35.76M | -11.97M | -7.63M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -2.25M | -348.00K | -328.00K | -43.00K | 0.00 |
| Net Income | -112.65M | -114.02M | -89.42M | -35.43M | -11.93M | -7.63M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -2.42 | -2.59 | -2.05 | -0.81 | -0.28 | -0.71 |
| EPS Diluted | -2.42 | -2.59 | -2.05 | -0.81 | -0.28 | -0.71 |
| Weighted Avg Shares Out | 46.58M | 44.07M | 43.60M | 43.48M | 43.33M | 10.80M |
| Weighted Avg Shares Out (Dil) | 46.58M | 44.07M | 43.60M | 43.48M | 43.33M | 10.80M |
Kinnate Biopharma (KNTE) Falls 40% in a Month: Here's Why
Kinnate Biopharma (KNTE) plunges 40% in a month for the decision to streamline its pipeline to one clinical candidate as part of its reprioritization efforts and slash workforce by 70%.
Kinnate Biopharma Inc. Announces Pipeline Updates, Strategic Reprioritization and Workforce Restructuring
SAN FRANCISCO and SAN DIEGO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate” or “the Company”), a clinical-stage precision oncology company, today announced pipeline updates and a reprioritization plan, as well as a workforce restructuring, based...
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
SAN FRANCISCO and SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the company will participate in two upcoming investor conferences:
7 Stocks With Promising Upside Potential for 100% Returns
While your friendly financial advisor will probably never recommend these terribly risky enterprises, sometimes, you're just in the mood for stocks with 100% upside potential. And with these ideas, you're going to get that and more, assuming the stars align...
4 Penny Stocks To Buy According To Insiders This Quarter
Insiders think these are penny stocks to buy based on recent filings but are they worth the risk? The post 4 Penny Stocks To Buy According To Insiders This Quarter appeared first on Penny Stocks to Buy, Picks, News and...
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting
SAN FRANCISCO and SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that a clinical trial abstract for its investigational pan-RAF inhibitor exarafenib has been selected for an...
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
SAN FRANCISCO and SAN DIEGO, Jan. 17, 2023 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced the poster presentation of the design and rationale of a Phase 1 trial-in-progress (KN-4802, NCT05242822) evaluating...
Kinnate Biopharma Inc. (KNTE) Upgraded to Buy: Here's What You Should Know
Kinnate Biopharma Inc. (KNTE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
SAN FRANCISCO and SAN DIEGO, June 01, 2022 (GLOBE NEWSWIRE) -- Kinnate Biopharma Inc. (Nasdaq: KNTE) (“Kinnate”), a clinical-stage precision oncology company, today announced that the company will participate in two upcoming in-person investor conferences:
Kinnate Biopharma Inc. to Present Trial Design for its Pan-FGFR Inhibitor Product Candidate, KIN-3248, at ASCO 2022
Preclinical data from a study of the Company's pan-RAF product candidate, KIN-2787, in combination with MEK inhibitor, also accepted for publication in the meeting proceedings Preclinical data from a study of the Company's pan-RAF product candidate, KIN-2787, in combination with...
Source: https://incomestatements.info
Category: Stock Reports